14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ELVN vs SYRE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 1–4 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas SYRE carries 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin).
Defensive Composite Rating Caution: Although ELVN compares more favorably head-to-head, both ELVN (35.9/100 SELL) and SYRE (36.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs SYRE. Trailing 12-month operating profitability (ELVN 0.0% vs SYRE 0.0%) and valuation multiples (ELVN N/M vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ELVN vs SYRE Key Questions & Quantitative Answers
As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 1–4 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas SYRE carries 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although ELVN compares more favorably head-to-head, both ELVN (35.9/100 SELL) and SYRE (36.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
ELVN and SYRE split Growth & Scale metrics: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.
ELVN and SYRE trade at balanced relative valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus SYRE (-35.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.